Organic LETTERS

Letter

Cite This: Org. Lett. XXXX, XXX, XXX−XXX

pubs.acs.org/OrgLett

A Strategy to Aminate Pyridines, Diazines, and Pharmaceuticals via Heterocyclic Phosphonium Salts

Chirag Patel, Margaret Mohnike, Michael C. Hilton, and Andrew McNally*

Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, United States

Supporting Information

ABSTRACT: A straightforward process to aminate pyridines and diazines is presented by reacting phosphonium salt derivatives with sodium azide. The iminophosphorane products are versatile precursors to several nitrogen-containing functional groups, and the process can be applied to building block heterocycles, to drug-like fragments, and for late-stage functionalization of complex pharmaceuticals. Appealing features of this strategy include using C−H bonds as precursors, precise regioselectivity, and a distinct scope from other amination methods, particularly those relying on halogenated azaarenes.



Extensive efforts have been dedicated toward aminating aromatic rings over the past several decades due to the widespread occurrence of aryl amines in pharmaceuticals, agrochemicals, natural products, and materials.[1] The most widely applied methods are metal-catalyzed C−N cross-coupling reactions, but several other distinct strategies have emerged, including radical-based methods, reactions with nitrogen electrophiles, nitroarene reduction processes, and C−H amination reactions (eq 1).[2−6] We became interested in this field after noticing that (a) aminopyridines and diazines are prominent in drug compounds (eq 2) and that (b) the number of broadly effective methods to aminate these heterocycles is considerably narrower than for benzene derivatives.[7−10] The classic Chichibabin reaction, which forms 2-aminopyridines from C−H precursors, lacks generality due to the excessive reactivity of $NaNH_2$.[11,12] Most methods rely on prehalogenated substrates such as Buchwald−Hartwig reactions, recent Ni-catalyzed cross-couplings, and S_NAr reactions.[2a,f,13] While these are powerful approaches, they can be limited by the lack of methods that can selectively install halides on more complex pyridines and diazines. As such, an alternative approach that produces a distinct set of aminated products would be valuable to medicinal chemists.

We are engaged in a program aimed at selectively transforming pyridine and diazine C−H bonds into phosphonium ions and then exploiting the reactivity of the C−P bond to make useful heterocyclic derivatives. Ourselves and Anders reported a single example of transforming the C−$^+PPh_3$ group into an iminophosphorane using NaN_3 as a nucleophile; however, we did not know if this strategy would be general across a range of pyridines and diazines.[14,15] We were therefore compelled to investigate this process further, as phosphonium salts can be formed on azaarenes that are often outside of the scope of current halogenation methods (eq 3). For example, Hartwig's AgF_2-mediated pyridine fluorination can be used to introduce amines at the 2-position,[16] whereas phosphonium salt formation is selective for the 4-position of the scaffold. We herein report that this phosphorus-mediated strategy can be broadly applied to selectively aminate building block heterocycles, drug-like fragments, and complex pharmaceuticals. Iminophosphoranes are also versatile functional groups that enable access to valuable nitrogen-containing derivatives.



Our first priority was to build on the preliminary result by investigating reaction parameters to obtain a standard amination protocol. We found that heating 2-phenyl phosphonium salt in the presence of sodium azide in DMSO at 120 °C was optimal, in terms of temperature and that increasing the concentration of the reaction to 1.5 M also increased the yield of the reaction. Although it is possible to use

Received: March 13, 2018

DOI: 10.1021/acs.orglett.8b00813
Org. Lett. XXXX, XXX, XXX−XXX

Scheme 1. Scope of the Phosphorus-Mediated Amination Process[a,b]



[a]Isolated yields of products are shown with yields of phosphonium salts in parentheses. [b]A red dot indicates the position of phosphonium salt regioisomers. Iminophosphoranes are isolated as single regioisomers in all cases.

solvents other than DMSO as the reaction medium, the reaction efficiency suffers (see Supporting Information (SI) for further details). Small amounts of the corresponding C–H heterocyclic precursor are obtained in the reaction, which can be separated via column chromatography.

With an optimized amination reaction in hand, we began exploring the generality of this amination process. Starting with pyridines, we selected scaffolds displaying a variety of substitution patterns and functional groups. In all cases, phosphonium salt formation and subsequent amination is exclusively selective for the 4-position (Scheme 1A). Tetrahydroquinoline, bearing a 2,3-substitution pattern, is smoothly aminated using this protocol (**2a**). Similarly, 2,5-disubstituted pyridines bearing substituents, including trifluoromethyl, thiomethyl, cyano groups, and aryl ethers, are effective (**2b**–**2d**). Sterically hindered 3,5-disubstituted pyridines also see C–N bond formation selectively occur at the 4-position (**2e** and **2f**). If the 4-position is blocked, then the 2-position is aminated instead, as shown for pyridine **2g** and quinoline **2h**. Diazines are also compatible with this approach: aminopyrazine **2i** and aminoquinoxaline **2j** are obtained in reasonable yields. Pyrimidines **2k** and **2l** work particularly well in the C–N bond-forming step, and although the synthesis of pyrrolopyrimidine **2m** was less efficient, it still gives access to a motif found in drugs such as tofacitinib (eq 2).

Then, we turned our attention to drug-like fragments with pyridines and diazines in their structures.[17] These types of molecules are abundant in pharmaceutical compound collections, and applying the amination protocol would result in important amino derivatives. However, their structures are often complex with other functional groups and basic nitrogen atoms present, making C–N bond formation challenging. Scheme 1B shows that a diverse set of representative drug fragments can be converted into iminophosphoranes using this two-step process. Iminophosphorane **2n**, containing a tri(hetero)aryl methane motif, is formed in good overall yield. Similarly, benzhydryl stereocenters are accommodated in pyridine **2o**, without interference from the piperidine moiety. Distinct pyrimidine-containing fragments, such as **2p** and **2q**, are particularly effective in this strategy. Finally, tri(hetero)aryl

DOI: 10.1021/acs.orglett.8b00813
Org. Lett. XXXX, XXX, XXX–XXX

systems **2r** and **2s** are noteworthy due to the potential isomeric mixtures of iminophosphoranes between the different pyridine rings; a single regio- and site-selective outcome was observed in each case.

Late-stage functionalization of pharmaceuticals is being intensively investigated at present, although strategies to aminate complex pyridines and diazines are limited.[18] Outside of Hartwig's 2-fluorination reaction, iridium-catalyzed borylation is the most promising strategy for aminating azaarenes, as the C−B bond can be used as a coupling handle to introduce an amine.[16,19] Our previous studies have shown that complex pharmaceuticals can be converted into phosphonium salts with excellent regio- and site-selectivity;[14a,b] successfully applying the subsequent azide coupling reaction would therefore represent an important method for late-stage amination. Scheme 1C shows that the two-step sequence is straightforward to apply to a set of structurally diverse pharmaceuticals. Chlorphenamine, a common antihistamine, is converted into iminophosphorane **2t** with exclusive regioselectivity over two steps. The C−N bond-forming step for loratadine occurs with lower yield, but in quantities that would be usable for medicinal chemists (**2u**). Benzyl-protected varenicline (**2v**), containing a quinoxaline ring, can also be aminated via this strategy. The site-selectivity issues in etoricoxib and imatinib are overcome using this phosphorus-mediated approach; the C−P bond is formed exclusively at the 4-position of the 2,5-disubstituted pyridine in etoricoxib and with 20:1 selectivity for pyridine versus pyrimidine in imatinib. Subsequent iminophosphorane formation proceeds efficiently, resulting in etoricoxib derivative **2w**. When the corresponding gleevec salt was aminated, we observed that appreciable amounts of the iminophosphorane hydrolyze under the reaction conditions. After consumption of the salt, water was added to the reaction mixture, and stirring at room temperature results in aniline derivative **2x**. In general, hydrolysis under the reaction conditions is a minor pathway in a small number of cases in this study; we believe that the adjacent aminopyrimidine ring in gleevec and conformation effects are responsible for this outcome.

Scheme 1D indicates some of the limitations of the C−N bond-forming reaction. Halogenated pyridines, in both the 2- and 3-positions, can undergo competitive S_NAr processes, and the corresponding organoazides are detected by LCMS analysis. Methoxy-substituted pyridines can undergo dealkylation reactions with NaN_3 that diminish the yields of the reaction. Pyridines substituted with amines are also challenging substrates; we attribute this deficiency to the electron-donating nature of these groups that slow down the coupling process.

We next derivatized the iminophosphorane within **2a** to show that this versatile functional group can give access to useful nitrogen-containing products (Scheme 2). Hydrolysis to the heteroaryl aniline, **3aa**, occurs by heating under neutral aqueous conditions.[20] Stirring the iminophosphorane in carbon disulfide forms isothiocyanate **3ab** in reasonable yield and is another versatile functional group that can be used to access carbonyl derivatives and heterocycles.[21] Finally, combining the iminophosphoranes with alkyl halides, followed by stirring in acidic protic media, is a simple protocol to obtain alkylated derivatives (**3ac**).[22]

Two mechanisms can be envisioned to form the iminophosphorane products that both proceed via an organoazide intermediate, followed by a Staudinger reaction (Scheme 3A). First, sodium azide adds to the phosphonium ion, and the resulting phosphorane undergoes ligand coupling to form the

Scheme 2. Derivatizations of Iminophosphoranes



[a]Isolated yields of products are shown.

Scheme 3. Mechanistic Pathways and Evidence of an Organoazide Intermediate



C−N bond.[23] Second, a S_NAr reaction where NaN_3 reacts at the *ipso* carbon and forms a Meisenheimer complex that then decomposes to release PPh_3. We favor an S_NAr process, given that polar solvents are most suitable and that the reaction is most effective on pyridines with electron-withdrawing substituents and diazine systems.[24] Scheme 3B provides evidence of a discrete organoazide intermediate. When 2-phenyl phosphonium salt was subjected to standard conditions in the presence of 1 equiv of $PTol_3$, a mixture of two iminophosphoranes is observed in the crude LCMS and ^{31}P NMR, indicating that the organoazide intermediate can be intercepted by an external nucleophile.

In summary, we have developed a simple and broadly applicable strategy to aminate pyridines and diazines. The heterocycle is first converted into a phosphonium salt and then heated with sodium azide to form useful iminophosphorane derivatives. The reaction is exclusively regioselective in almost every case and can be applied on drug-like fragments and as a tool for late-stage functionalization of pharmaceuticals. The iminophosphorane is a versatile handle providing access to other important nitrogen-containing molecules, making this strategy particularly valuable for medicinal chemists.

DOI: 10.1021/acs.orglett.8b00813
Org. Lett. XXXX, XXX, XXX−XXX

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.8b00813.

Experimental procedures and spectral data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: andy.mcnally@colostate.edu.

ORCID

Andrew McNally: 0000-0002-8651-1631

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by start-up funds from Colorado State University and The National Institutes of Health under award number R01 GM124094-01.

■ REFERENCES

(1) (a) Lawrence, S. A. *Amines: Synthesis, Properties and Applications*; Cambridge University Press: Cambridge, UK, 2004. (b) Corbet, J.-P.; Mignani, G. *Chem. Rev.* **2006**, *106*, 2651.

(2) (a) Surry, D. S.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 6338. (b) Surry, D. S.; Buchwald, S. L. *Chem. Sci.* **2011**, *2*, 27. (c) Hartwig, J. F. *Acc. Chem. Res.* **2008**, *41*, 1534. (d) Ley, S. V.; Thomas, A. W. *Angew. Chem., Int. Ed.* **2003**, *42*, 5400. (e) Kienle, M.; Dubbaka, S. R.; Brade, K.; Knochel, P. *Eur. J. Org. Chem.* **2007**, *2007*, 4166. (f) Corcoran, E. B.; Pirnot, M. T.; Lin, S.; Dreher, S. D.; DiRocco, D. A.; Davies, I. W.; Buchwald, S. L.; MacMillan, D. W. C. *Science* **2016**, *353*, 279. (g) Li, C.; Kawamata, Y.; Nakamura, H.; Vantourout, J. C.; Liu, Z.; Hou, Q.; Bao, D.; Starr, J. T.; Chen, J.; Yian, M.; Baran, P. S. *Angew. Chem., Int. Ed.* **2017**, *56*, 13088. (h) Tasker, S. Z.; Standley, E. A.; Jamison, T. F. *Nature* **2014**, *509*, 299. (i) Ge, S.; Green, R. A.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 1617. (j) Shin, K.; Kim, H.; Chang, S. *Acc. Chem. Res.* **2015**, *48*, 1040.

(3) Selected examples of radical-based methods: (a) Foo, K.; Sella, E.; Thomé, I.; Eastgate, M. D.; Baran, P. S. *J. Am. Chem. Soc.* **2014**, *136*, 5279. (b) Romero, N. A.; Margrey, K. A.; Tay, N. E.; Nicewicz, D. A. *Science* **2015**, *349*, 1326. (c) Allen, L. J.; Cabrera, P. J.; Lee, M.; Sanford, M. S. *J. Am. Chem. Soc.* **2014**, *136*, 5607.

(4) (a) Kattamuri, P. V.; Yin, J.; Siriwongsup, S.; Kwon, D.-Y.; Ess, D. H.; Li, Q.; Li, G.; Yousufuddin, M.; Richardson, P. F.; Sutton, S. C.; Kürti, L. *J. Am. Chem. Soc.* **2017**, *139*, 11184. (b) Zhou, Z.; Ma, Z.; Behnke, N. E.; Gao, H.; Kürti, L. *J. Am. Chem. Soc.* **2017**, *139*, 115. (c) Paudyal, M. P.; Adebesin, A. M.; Burt, S. R.; Ess, D. H.; Ma, Z.; Kürti, L.; Falck, J. R. *Science* **2016**, *353*, 1144. (d) Kim, H. J.; Kim, J.; Cho, S. H.; Chang, S. *J. Am. Chem. Soc.* **2011**, *133*, 16382. (e) Yan, X.; Yang, X.; Xi, C. *Catal. Sci. Technol.* **2014**, *4*, 4169.

(5) (a) Gui, J.; Pan, C.-M.; Jin, Y.; Qin, T.; Lo, J. C.; Lee, B. J.; Spergel, S. H.; Mertzman, M. E.; Pitts, W. J.; La Cruz, T. E.; Schmidt, M. A.; Darvatkar, N.; Natarajan, W. R.; Baran, P. S. *Science* **2015**, *348*, 886. (b) Cheung, C. W.; Hu, X. *Nat. Commun.* **2016**, *7*, 12494.

(6) Selected examples: (a) Shrestha, E.; Mukherjee, P.; Tan, Y.; Litman, Z. C.; Hartwig, J. F. *J. Am. Chem. Soc.* **2013**, *135*, 8480. (b) Boursalian, G. B.; Ngai, M.-Y.; Hojczyk, K. N.; Ritter, T. *J. Am. Chem. Soc.* **2013**, *135*, 13278. (c) Shin, K.; Kim, H.; Chang, S. *Acc. Chem. Res.* **2015**, *48*, 1040. (d) Yoo, S.; Ma, E. J.; Mei, T.-S.; Chan, K. S. L.; Yu, J.-Q. *J. Am. Chem. Soc.* **2011**, *133*, 7652.

(7) Burger, J. A.; Buggy, J. J. *Leuk. Lymphoma* **2013**, *54*, 2385.

(8) Cutolo, M.; Meroni, M. *J. Inflammation Res.* **2013**, *6*, 129.

(9) Milelli, A.; De Simone, A.; Ticci, N.; Chen, H. H.; Betari, N.; Andrisano, V.; Tumiatti, V. *Curr. Med. Chem.* **2017**, *24*, 3522.

(10) Al-Bari, M. A. A. *J. Antimicrob. Chemother.* **2015**, *70*, 1608.

(11) McGill, C. K.; Rappa, A. *Adv. Heterocycl. Chem.* **1988**, *44*, 1.

(12) Yin, J.; Xiang, B.; Huffman, M. A.; Raab, C. E.; Davies, I. W. *J. Org. Chem.* **2007**, *72*, 4554.

(13) Smith, M. B.; March, J. *Advanced Organic Chemistry*, 5th ed.; Wiley-Interscience: New York, NY, 2001.

(14) (a) Hilton, M. C.; Dolewski, R. D.; McNally, A. *J. Am. Chem. Soc.* **2016**, *138*, 13806. (b) Zhang, X.; McNally, A. *Angew. Chem., Int. Ed.* **2017**, *56*, 9833. (c) Koniarczyk, J. L.; Hesk, D.; Overgard, I.; Davies, I. W.; McNally, A. *J. Am. Chem. Soc.* **2018**, *140*, 1990. (d) Anders, E.; Markus, F. *Tetrahedron Lett.* **1987**, *28*, 2675. (e) Anders, E.; Markus, F. *Chem. Ber.* **1989**, *122*, 113. (f) Anders, E.; Markus, F. *Chem. Ber.* **1989**, *122*, 119. (g) Haase, M.; Goerls, H.; Anders, E. *Synthesis* **1998**, *1998*, 195.

(15) For a review on functionalizing activated pyridines and recent examples, see: (a) Bull, J. A.; Mousseau, J. J.; Pelletier, G.; Charette, A. B. *Chem. Rev.* **2012**, *112*, 2642. (b) Fier, P. S. *J. Am. Chem. Soc.* **2017**, *139*, 9499. (c) Elbert, B. L.; Farley, A. J. M.; Gorman, T. W.; Johnson, T. C.; Genicot, C.; Lallemand, B.; Pasau, P.; Flasz, J.; Castro, J. L.; MacCoss, M.; Paton, R. S.; Schofield, C. J.; Smith, M. D.; Willis, M. C.; Dixon, D. J. *Chem. - Eur. J.* **2017**, *23*, 14733.

(16) Fier, P. S.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 10139.

(17) (a) Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. *Nat. Rev. Drug Discovery* **2016**, *15*, 605. (b) Murray, C. W.; Rees, D. C. *Nat. Chem.* **2009**, *1*, 187.

(18) Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. *Chem. Soc. Rev.* **2016**, *45*, 546.

(19) Larsen, M. A.; Hartwig, J. F. *J. Am. Chem. Soc.* **2014**, *136*, 4287.

(20) Vaultier, M.; Knouzi, N.; Carrié, R. *Tetrahedron Lett.* **1983**, *24*, 763.

(21) Molina, P.; Vilaplana, M. J. *Synthesis* **1994**, *1994*, 1197.

(22) Palacios, F.; Aparicio, D.; Garcia, J. *Tetrahedron* **1998**, *54*, 1647.

(23) Finer, J.-P. *Ligand Coupling Reactions with Heteroaromatic Compounds*, Tetrahedron Organic Chemistry Series; Pergamon Press: Oxford, 1998; Vol. *18*, chap. 4.

(24) The reactivity trends for this C−N bond-forming reaction are noticeably different from our previously reported C−O coupling in reference 14a.

DOI: 10.1021/acs.orglett.8b00813
Org. Lett. XXXX, XXX, XXX−XXX